Knight Therapeutics (TSX:GUD) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.01) by 1385.71 percent. This is a 18.18 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $133.106 million which beat the analyst consensus estimate of $115.998 million by 14.75 percent. This is a 37.42 percent increase over sales of $96.864 million the same period last year.